首页> Immunotherapy> Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.

Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniel,Suez

第一单位： Allergy, Asthma & Immunology Clinic, PA, Irving, TX 75063, USA.

作者： Daniel,Suez ^[1] ; Gergely,Kriván ^[2] ; Stephen,Jolles ^[3] ; Mark,Stein ^[4] ; Sudhir,Gupta ^[5] ; Kenneth,Paris ^[6] ; P Martin,van Hagen ^[7] ; Nicholas,Brodszki ^[8] ; Werner,Engl ^[9] ; Heinz,Leibl ^[10] ; Barbara,McCoy ^[10] ; Leman,Yel ^[11]

作者单位： Allergy, Asthma & Immunology Clinic, PA, Irving, TX 75063, USA. ^[1] Department of Pediatric Hematology & Stem Cell Transplantation, Szent László Hospital, Budapest, Hungary. ^[2] Immunodeficiency Centre for Wales, University Hospital of Wales, Heath Park, Cardiff, UK. ^[3] Allergy Associates of the Palm Beaches, North Palm Beach, FL 33408, USA at the time of this study. ^[4] Division of Basic & Clinical Immunology, University of California at Irvine, Irvine, CA 92697, USA. ^[5] Department of Pediatrics, LSU Health Sciences Center New Orleans, Children's Hospital of New Orleans, New Orleans, LA 70118, USA. ^[6] Department of Internal Medicine/Clinical Immunology, Erasmus University Medical Center, Rotterdam, Netherlands. ^[7] Department of Pediatric Oncology/Immunology, Skåne University Hospital, Lund, Sweden. ^[8] Biostatistics, The Takeda Group of Companies, Vienna, Austria. ^[9] Clinical Research Immunology, The Takeda Group of Companies, Vienna, Austria. ^[10] Research & Development, Plasma Derived Therapies Business Unit, The Takeda Group of Companies, Cambridge, MA 02142, USA.;Department of Medicine, University of California at Irvine, CA 92697, USA. ^[11]

关键词 CUVITRU Ig20Gly common variable immune deficiency immunoglobulin immunoglobulin replacement therapy (IgRT)primary immunodeficiency safety subcutaneous tolerability